Testiscancer's profile picture. Senior testis cancer doc.  Founder testicular cancer commons,  PI S1823, mentor of youngsters, father of farmers. Opinions my own

Craig Nichols

@Testiscancer

Senior testis cancer doc. Founder testicular cancer commons, PI S1823, mentor of youngsters, father of farmers. Opinions my own

Craig Nichols reposted

Willamette!!


JCO Comments and Controversies piece out. Provides rationale for PRESTIGE and MAGESTIC trials to come. Thanks @UroAlsyouf @siadaneshmand @LuciaNappi4 DOI: 10.1200/JCO.22.02002


Case for pRPLND as chemo-sparing approach in CSII NS becoming stronger. @moosemousa @RHamiltonUrol #AUA2023 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR METASTATIC NONSEMINOMATOUS GERM CELL TUMOR:


Testis cancer oral abstracts ASCO pick up nicely on two emerging likely practice changing themes. miR371 (@LuciaNappi4) and primary RPLND in early regional seminoma (T. Tandstad). Can't wait


Well. . . This is a bit awkward. ChatGPT appears to be as good at poetry as it is at understanding clinical trial design, conduct, actual patient impact and cogent debate

When it comes to debating Stage 2 seminoma management, #ChatGPT has the final say.

Kenrickng1's tweet image. When it comes to debating Stage 2 seminoma management, #ChatGPT has the final say.


While not a lot of new information, the article is important in that it reiterates the high baseline of CVD risk factors (with or without cisplatin) for men as they move into their 40s/ 50s. Should have low threshold for management of HTN, dyslipidemia, obesity, energy balance

Not ground breaking but worth reiterating. Chemo for GCT was revolutionary but strive to cure while minimizing exposure to it, legit long term baggage ⁦@Testiscancer⁩ ⁦@siadaneshmand⁩ ⁦@AdityaBagrodia⁩ ⁦@drphil_urologyascopubs.org/doi/full/10.12…



3 people followed me // automatically checked by fllwrs.com


Took Bard out for a spin. Not so impressive. Could not stage testis cancer and could not identify Larry Einhorn. Needs some work


Notified that S1823 will be presented as a poster in the Trials in Progress section #ASCO23. @SWOG @supportingSWOG @siadaneshmand, @uroegg,@nabiladra @LuciaNappi4,@RHamiltonUrol @AdityaBagrodia and Andrea Harzstark, SWOG biostats and the over 700 pts enrolled


one person followed me // automatically checked by fllwrs.com


Nice AUA abstract by Candelas-Gomez, Hamilton, Jewett et al re Canadian 2nd opinion in GCT. Mirrors England SWENTOTECA German efforts at hub and spoke care delivery


Remember this is PFS or TFS NOT OS which is 100%

🧐 First multi-institutional #ClinicalTrial details efficacy of retroperitoneal lymph node dissection in early metastatic #Seminoma ➡️ fal.cn/3x6AP #JCO #surgonc #tscsm @siadaneshmand @GU_Bigwhacks

JCO_ASCO's tweet image. 🧐 First multi-institutional #ClinicalTrial details efficacy of retroperitoneal lymph node dissection in early metastatic #Seminoma ➡️ fal.cn/3x6AP #JCO #surgonc #tscsm @siadaneshmand @GU_Bigwhacks


one person unfollowed me // automatically checked by fllwrs.com


Well, we will have at least one oral presentation at big #ASCO2023. Magnifico! @LuciaNappi4


AUA Abstracts are out. Expanding data sets for surgical management of CSII GCT @siadaneshmand, USC superstar young urologists and the whole network


3 people followed me // automatically checked by fllwrs.com


Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets? dailynews.ascopubs.org/do/emerging-cl…


Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets? ASCO Daily News piece out today with colleagues @LuciaNappi4 @siadaneshmand and C. Kollmannsberger


Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets? dailynews.ascopubs.org/do/emerging-cl…


3 people followed me and one person unfollowed me // automatically checked by fllwrs.com


Loading...

Something went wrong.


Something went wrong.